

OncoTherapy Science, Inc.

January 26, 2016

The commencement of Phase Ib clinical study of the peptide vaccine
for patients with malignant mesothelioma

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, “OncoTherapy”) announces that the commencement of Phase Ib clinical study of the vaccine of a mixture of five oncoantigen peptides whose intellectual property rights are owned by OncoTherapy and were exclusively licensed to a pharmaceutical company, for patients with malignant mesothelioma was approved by the US Food and Drug Administration (FDA) and the medical center’s Institutional Review Board at the University of Chicago. All procedures to conduct this study have been completed.

This study for patients with malignant mesothelioma is conducted to evaluate the immune response after the treatment of the vaccines derived from five oncoantigens at University of Chicago as an investigator-initiated trial.

OncoTherapy has been and will facilitate the strategic dialogue with our licensing-out partners, and enforces the indirect and logistic supports for clinical development conducted by these partners. Thus, the clinical developments for our cancer-specific peptide vaccines are conducted in Japan, USA and Europe at present.